Life Science Investing ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy®
Life Science Investing ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
Life Science Investing neffy® Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions
Life Science Investing Real-World Evidence Supports Clinical Effectiveness of neffy® in Patients Experiencing Anaphylaxis
Life Science Investing ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy®
life science investing ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
life science investing ARS Pharmaceuticals Submits Response for neffy® Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
